Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fed Condition

Phase 1 Completed 28 enrolled Daewon Pharmaceutical Co., Ltd. Asan Medical Center · collab

RandomizedCrossoverOpen-labelSupportive care

Summary

The purpose of this study is to evaluate pharmacokinetics of Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in healthy male volunteers under fed condition.

Timeline

Start: 2012-04
Primary completion: 2012-06
Completion: 2012-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Megestrol Acetate	Other / unclassified	625 mg	—
Comparator	Megestrol Acetate	Other / unclassified	800 mg	—

Indications

No indication recorded.